<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Levin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intracoronary thrombosis and the attendant risk of myocardial ischemia or infarction may occur soon after percutaneous coronary intervention with stent implantation. Trauma to the coronary endothelium (with the exposure of tissue factors to blood) and placement of metal (which is procoagulant) stents are causative. Stent thrombosis can be a life-threatening event. (See  <a class="medical medical_review" href="/d/html/87310.html" rel="external">"Coronary artery stent thrombosis: Clinical presentation and management"</a> and  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a>.)</p><p>Antithrombotic therapy, with both antiplatelet and anticoagulant medications, is used to reduce the risk. Early studies of antithrombotic therapy demonstrated a reduction in early stent thrombosis. (See  <a class="medical medical_review" href="/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a> and  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a>.)</p><p>The clinical trials evaluating antithrombotic therapy at the time of stent implantation will be reviewed here. Recommendations for the use of such therapy in stable patients and the use of antiplatelet and anticoagulant strategies in patients with acute coronary syndromes are discussed separately. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a>.)</p><p>The discussion of and the recommendations for long-term dual antiplatelet therapy is found elsewhere. (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANTIPLATELET THERAPY</span><span class="headingEndMark"> — </span>All patients receive periprocedural <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> receptor blocker. A glycoprotein (GP) IIb/IIIa inhibitor is given to some patients.</p><p class="headingAnchor" id="H3"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> is recommended for all patients with coronary artery disease. (See  <a class="medical medical_review" href="/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> is specifically recommended for patients undergoing coronary stenting, based primarily upon data from early randomized trials of aspirin or aspirin plus <a class="drug drug_general" data-topicid="9377" href="/d/drug information/9377.html" rel="external">dipyridamole</a> compared to placebo in patients undergoing percutaneous transluminal coronary (balloon) angioplasty [<a href="#rid1">1,2</a>]. </p><p>The benefit from <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> seen in the above trials [<a href="#rid1">1,2</a>] was found in an observational study of 65,175 patients who underwent percutaneous coronary intervention (PCI) between 2010 and 2011 [<a href="#rid3">3</a>]. In this population, 7.1 percent of patients were not given aspirin within 24 hours before the procedure. In a (1:1) propensity-matched analysis of 4640 individuals who did and 4640 who did not receive aspirin, the absence of aspirin was associated with a higher rate of death (3.9 versus 2.8 percent; odds ratio [OR] 1.89, 95% confidence interval [CI] 1.32-2.71) and stroke (0.5 versus 0.1 percent; OR 4.24, 95% CI 1.59-12.11).</p><p class="headingAnchor" id="H4"><span class="h2">P2Y12 receptor blockers</span><span class="headingEndMark"> — </span>The thienopyridines <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a>, and <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> and the non-thienopyridines <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> and <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a> achieve their antiplatelet effect by inhibiting the P2Y12 receptor, resulting in reduced platelet activation and subsequent aggregation [<a href="#rid4">4</a>]. </p><p><a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">Ticlopidine</a> or <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (on top of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy) have been extensively evaluated in stable patients undergoing stent implantation.</p><p class="headingAnchor" id="H5"><span class="h3">Ticlopidine</span><span class="headingEndMark"> — </span>Early randomized trials found that <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a> plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> was more effective than aspirin alone for preventing stent thrombosis in patients receiving bare metal stents [<a href="#rid5">5-11</a>]. However, ticlopidine is rarely used in clinical practice, as hematologic side effects limit its use. (See  <a class="medical medical_review" href="/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Ticlopidine'</a> and  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'P2Y12 receptor blockers'</a>.)</p><p class="headingAnchor" id="H1136003648"><span class="h3">Clopidogrel</span></p><p class="headingAnchor" id="H6"><span class="h4">Efficacy and safety</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> has been shown to have equal efficacy to <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a> in terms of major cardiac events [<a href="#rid12">12-16</a>] and a lower rate of major side effects [<a href="#rid12">12,13,17,18</a>]. </p><p>In the CLASSICS trial, the adverse event rate (major bleeding complications, thrombocytopenia, neutropenia, or early discontinuation of drug for a noncardiac adverse event) was significantly lower in the patients treated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (4.6 versus 9.1 percent with <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a>) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Problems with clopidogrel use'</a>.)</p><p class="headingAnchor" id="H7"><span class="h4">Timing and dose</span><span class="headingEndMark"> — </span>The CREDO trial confirmed the benefit of pretreatment with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> in more than 2100 patients undergoing elective PCI (almost all with stenting) [<a href="#rid19">19</a>]. The patients were randomly assigned to pretreatment with placebo or clopidogrel at a loading dose of 300 mg 3 to 24 hours before the procedure; after the procedure, all patients received clopidogrel (75 mg/day) for 28 days; clopidogrel or placebo, according to original randomization, was then given for the remainder of one year. All received <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for the duration of the study, and more than 40 percent of patients also received concomitant therapy with an intravenous GP IIb/IIIa inhibitor. The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>At 28 days, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> therapy was associated with a nonsignificant reduction in the combined end point of death, myocardial infarction (MI), or urgent target vessel revascularization (6.8 versus 8.3 percent, relative risk [RR] reduction 18.5 percent, 95% CI 14.2-41.8). In a prespecified subset analysis, a strong trend for reduction in these events was seen when clopidogrel was begun ≥6 hours before the procedure (RR reduction 38.6 percent, 95% CI -1.6 to +62.9 percent), with no benefit with shorter pretreatment intervals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At one year, the combined end point of MI, stroke, and death was significantly reduced by loading and long-term <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (8.5 versus 11.5 percent with placebo, RR reduction 26.9 percent, 95% CI 3.9-44.4).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent subgroup analysis showed that the benefit of the <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> loading dose was first significant when given at least 15 hours before PCI and was greatest when given at least 24 hours before PCI [<a href="#rid20">20</a>]. The absolute risk reduction in patients with ≥15 hours of clopidogrel pretreatment was 6.2 percent compared to placebo pretreatment in the same time interval (3.5 versus 9.7 percent). The risk reduction with prolonged clopidogrel pretreatment was greatest in patients who did not receive a GP IIb/IIIa inhibitor.</p><p></p><p>For patients who cannot receive <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> within 15 hours of the procedure, this time limitation may be overcome by giving a clopidogrel loading dose of more than 300 mg, the dose used in CREDO. Evidence for efficacy within two to three hours of administration of 600 mg comes from the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>The time dependence of platelet inhibition after 600 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> was evaluated in an unselected cohort of 1001 patients scheduled for possible PCI [<a href="#rid21">21</a>]. The maximum antiplatelet effect using several in vitro measures was seen by two hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ISAR-REACT trial evaluated the efficacy of abciximab in 2159 patients undergoing elective PCI [<a href="#rid22">22</a>]. All patients were pretreated with 600 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> at least two hours before PCI. When the study subjects were grouped into four subsets based upon duration of clopidogrel pretreatment (two to three hours, three to six hours, 6 to 12 hours, and &gt;12 hours), there was no significant difference among the four groups in the incidence of death, MI, or urgent revascularization at 30 days or in the rate of major bleeding.</p><p></p><p>The higher loading dose also may improve outcomes [<a href="#rid23">23,24</a>]. This was suggested in the ARMYDA-2 trial in which 255 patients (75 percent stable angina, 25 percent non-ST elevation acute coronary syndrome [ACS]) scheduled to undergo PCI were randomly assigned to a 300 or 600 mg loading dose four to eight hours before the procedure [<a href="#rid23">23</a>]. All but two patients received a stent and only 13 percent were treated with a GP IIb/IIIa inhibitor.</p><p>The primary end point (death, MI, or target vessel revascularization) occurred significantly less often with the 600 mg loading dose (4 versus 12 percent), a difference that was entirely due to a lower rate of periprocedural MI (4.0 versus 11.6 percent, adjusted odds ratio 0.48). Major bleeding did not occur in either group, but the authors could not comment on bleeding risk if emergency coronary artery bypass graft surgery (CABG) were required.</p><p>The following mechanisms may contribute to the apparently better outcome with the 600 mg loading dose:</p><p class="bulletIndent1"><span class="glyph">●</span>A 300 mg loading dose would not be fully active when given four to eight hours before PCI [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 600 mg loading dose produces a greater maximal antiplatelet effect [<a href="#rid24">24-28</a>], an earlier antiplatelet effect (the degree of platelet inhibition at two hours is greater than the maximal effect with 300 mg, which is also seen later) [<a href="#rid27">27</a>], and may diminish the likelihood of both <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> resistance [<a href="#rid29">29</a>] and of a reduced antiplatelet effect in patients taking drugs that are metabolized by CYP3A4 [<a href="#rid21">21,30</a>]. (See  <a class="medical medical_review" href="/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Definitions'</a>.)</p><p></p><p>The need to give <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> hours before PCI is potentially problematic for patients referred for diagnostic coronary arteriography, since many of these patients do not have coronary artery disease requiring intervention and some will have disease requiring early CABG. Both of these groups would therefore be unnecessarily exposed to any bleeding risk associated with clopidogrel therapy. These issues were addressed in the PRAGUE-8 and ARMYDA-5 PRELOAD trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In PRAGUE-8, 1028 stable patients were randomly assigned to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 600 mg given either more than six hours before or immediately after elective coronary arteriography in patients undergoing PCI [<a href="#rid31">31</a>]. PCI was performed in 29 percent of patients and CABG in 12 percent. There was no significant difference between the two regimens in a combined primary clinical end point (death/MI, stroke, transient ischemic attack, repeat PCI, 0.8 versus 1.0 percent), but there was a statistically significant increase in the rate of bleeding (mostly minor) in those who received the earlier clopidogrel dose (3.5 versus 1.4 percent). However, there were several important limitations of this trial, including the small number of patients undergoing PCI and a higher-than-expected rate of bleeding complications [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In ARMYDA-5 PRELOAD, 409 patients (61 percent with stable angina, 39 percent with non-ST elevation MI) were randomly assigned to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 600 mg either four to eight hours before or immediately after coronary angiography (but before PCI) [<a href="#rid33">33</a>]. There was no significant difference in the 30-day incidence of major adverse cardiac events of cardiac death, MI, or unplanned target vessel revascularization (10.3 versus 8.8 percent) nor was there a difference in the rates of either risk of bleeding/vascular complications (7.8 versus 5.4 percent). A post-hoc subgroup analysis of the patients with stable angina showed no significant difference in these events. </p><p></p><p>The issue of whether patients already taking <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 75 daily need to be reloaded at the time of PCI is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'P2Y12 receptor blockers'</a>.)</p><p>The duration of dual antiplatelet therapy is an important issue that is discussed separately. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'P2Y12 receptor blockers'</a>.) </p><p class="headingAnchor" id="H9"><span class="h3">Cangrelor</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">Cangrelor</a> is an intravenous (non-thienopyridine) adenosine triphosphate analogue that blocks the adenosine diphosphate P2Y<sub>12</sub> receptor. Advantages of cangrelor, which might improve clinical outcomes over other antiplatelet agents, are its rapid onset of action and rapid return of platelet function after cessation. Our recommendations for the use of cangrelor in patients undergoing PCI, based on the studies below, are found elsewhere. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'P2Y12 receptor blockers'</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving primary PCI'</a> and  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'P2Y12 use'</a>.)</p><p>Two early trials evaluated <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a> in patients undergoing PCI and both failed to show clinical superiority to <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid34">34,35</a>]. In both trials, which enrolled patients with ACS or stable angina requiring PCI, cangrelor infusion was given for two hours or for the duration of the procedure, whichever was longer:</p><p class="bulletIndent1"><span class="glyph">●</span>In the CHAMPION PLATFORM trial, over 5000 patients were randomly assigned to either <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a> infusion or placebo 30 minutes before PCI, followed by 600 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> after the procedure in both groups [<a href="#rid34">34</a>]. There was no significant difference in the primary composite end point (death, MI, or ischemia-driven revascularization) at 48 hours (7.0 versus 8.0 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CHAMPION PCI trial, almost 8000 patients were randomly assigned to either <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a> infusion or 600 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> given 30 minutes before PCI [<a href="#rid35">35</a>]. Using an identical primary end point as CHAMPION PLATFORM, there was no significant difference between cangrelor and clopidogrel (7.5 versus 7.1 percent respectively) at 48 hours. </p><p></p><p>A third trial, CHAMPION PHOENIX, randomly assigned 11,145 patients undergoing urgent or elective PCI to receive a bolus and infusion of <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a> or a loading dose of either 600 or 300 mg of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid36">36</a>]. At 48 hours, the rate of the composite primary efficacy end point (death, MI, ischemia-driven revascularization, or stent thrombosis) occurred less often in the cangrelor group (4.7 versus 5.9 percent; adjusted odds ratio 0.78, 95% CI 0.66-0.93). There was no significant difference in the rate of the primary safety end point of severe or life-threatening bleeding at 48 hours (0.16 versus 0.11 percent; odds ratio 1.50, 95% CI 0.53-4.22). In a sensitivity analysis published separately, cangrelor reduced the incidence of MI at 48 hours (3.8 versus 4.7 percent; odds ratio 0.80, 95% CI 0.67-0.97) [<a href="#rid37">37</a>].</p><p>In a pooled analysis of patient-level data from the three CHAMPION trials (12 percent ST-elevation MI, 57 percent non-ST elevation ACS, and 31 percent stable disease), <a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">cangrelor</a>, compared to control (<a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or placebo), lowered the rate of primary composite efficacy end point of death, MI, ischemia-driven revascularization, or stent thrombosis at 48 hours (3.8 versus 4.7 percent; odds ratio 0.81, 95% CI 0.71-0.91) [<a href="#rid38">38</a>]. Mild, but not major, bleeding was increased with cangrelor (16.8 versus 13.0 percent). </p><p><a class="drug drug_general" data-topicid="102219" href="/d/drug information/102219.html" rel="external">Cangrelor</a> was approved for use by the United States Food and Drug Administration in June of 2015 as an adjunct to PCI in patients who have not been treated with a P2Y12 platelet inhibitor and who are not being given a glycoprotein IIb/IIIa inhibitor [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H1221867311"><span class="h3">Ticagrelor and prasugrel</span><span class="headingEndMark"> — </span>Two platelet P2Y<sub>12</sub> receptor blockers, <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> and <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>, have been evaluated in patients with ACS. The relevant trials and our recommendations for their use are presented separately. (See  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving primary PCI'</a> and  <a class="medical medical_review" href="/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Cilostazol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">Cilostazol</a> is approved for the treatment of intermittent claudication and its use has been associated with a reduction in the rate of restenosis after coronary stent placement. (See  <a class="medical medical_review" href="/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Cilostazol'</a>.)</p><p>As an inhibitor of type III phosphodiesterase in platelets, <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> is an effective antiplatelet agent. (See  <a class="medical medical_review" href="/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs"</a>.) Triple antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, and cilostazol compared to dual antiplatelet therapy with aspirin and clopidogrel has been evaluated in a few studies of patients with either stable or unstable coronary disease. In each of the studies below, cilostazol was given with a loading dose of 200 mg and then maintained at 100 mg twice daily, unless otherwise stated.</p><p>Short-term outcomes were evaluated in two studies and no difference between double and triple antiplatelet therapy was found [<a href="#rid41">41,42</a>]. Longer-term outcomes come from one randomized trial and two observational studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label, randomized trial of 1212 patients with ACS undergoing stent placement with either bare metal stents or drug-eluting stents (DES), patients were treated with either <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> (for six months; no loading dose given) in addition to aspirin and clopidogrel [<a href="#rid43">43</a>]. At one year, the primary end point (composite of cardiac death, nonfatal MI, stroke, or target vessel revascularization) occurred significantly less often in the group that received cilostazol (10.3 versus 15.1 percent; hazard ratio 0.65, 95% CI 0.41-0.91).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the KAMIR registry of patients with ST-elevation MI treated with primary PCI using DES, there were 2569 individuals who received <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> and 1634 who received <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> (for at least one month) in addition to aspirin and clopidogrel [<a href="#rid44">44</a>]. At eight months, patients who received cilostazol had significantly lower rates of cardiac death (2.0 versus 3.2 percent; adjusted odds ratio [OR] 0.52, 95% CI 0.32-0.84), and total major adverse cardiac events (all-cause mortality, nonfatal MI, and repeat PCI or revascularization procedure) (7.6 versus 9.3 percent; adjusted OR 0.74, 95% CI 0.58-0.95).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the DECREASE registry of patients with stable or unstable coronary disease who underwent stenting with DES, 1443 received <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> and 1656 received <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a> for at least four weeks in addition to aspirin and clopidogrel [<a href="#rid45">45</a>]. At 12 months, there was no significant difference between the two groups in combined rate of death, MI, or stent thrombosis. However, the hazard ratios for MI or stent thrombosis were significantly lower in those who received all three antiplatelet agents (0.23, 95% CI 0.08-0.70 and 0.14, 95% CI 0.04-0.52, respectively).</p><p></p><p>In all studies, there was no significant difference in the rate of major bleeding between groups.</p><p class="headingAnchor" id="H11"><span class="h2">GP IIb/IIIa inhibitors</span><span class="headingEndMark"> — </span>The efficacy of GP IIb/IIIa inhibitors in elective stenting was addressed in the EPISTENT and ESPRIT trials of patients undergoing elective stenting who were treated with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a> [<a href="#rid46">46-51</a>]. While these studies showed improved clinical outcomes at 30 days and one year, comparing a GP IIb/IIIa inhibitor to placebo, they were performed in an era prior to the routine use of P2Y12 inhibitor loading, more potent P2Y12 receptor inhibitors, and the use of direct thrombin inhibitors as anticoagulants. (See <a class="local">'P2Y12 receptor blockers'</a> above.)</p><p>A GP IIb/IIIa inhibitor may not provide any additional benefit in patients pretreated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>. This was demonstrated in the ISAR-REACT trial, in which 2159 patients with stable native vessel coronary disease and no major comorbidities underwent elective PCI (90 percent with stenting) at least two hours after pretreatment with 600 mg of clopidogrel (median duration of pretreatment 7.4 hours) [<a href="#rid52">52</a>]. The study subjects were randomly assigned to abciximab plus heparin (70 units/kg) or placebo plus heparin (100 to 140 units/kg). At 30 days, there was no difference in the incidence of death, MI, or urgent target vessel revascularization between abciximab and placebo (4 percent in each group). Major bleeding complications occurred in 1 percent of each group. A later follow-up at one year continued to show no effect of abciximab on death or MI [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Comparison of different agents</span><span class="headingEndMark"> — </span>The relative clinical efficacy of abciximab, <a class="drug drug_general" data-topicid="10288" href="/d/drug information/10288.html" rel="external">tirofiban</a>, and <a class="drug drug_general" data-topicid="8918" href="/d/drug information/8918.html" rel="external">eptifibatide</a> at currently recommended doses has been uncertain for patients undergoing PCI. The efficacy of any of the agents appears to be closely related to the degree of platelet inhibition achieved during and in the initial period after PCI [<a href="#rid54">54-56</a>]. This effect is clearly related to the potency of the initial bolus dose. The degree of platelet inhibition is similar at two hours after initiation of therapy [<a href="#rid54">54</a>], but the dosing regimen of tirofiban (10 mcg/kg bolus followed by 0.15 mcg/kg per min infusion) often produces a lesser degree of platelet inhibition compared to the other two agents in the clinically important period of 15 to 60 minutes after intervention [<a href="#rid55">55,57</a>].</p><p>The only trial that has directly compared the relative efficacy of two GP IIb/IIIa inhibitors was the TARGET trial, in which 4809 patients who underwent nonemergent stent-based PCI were randomly assigned to abciximab (0.25 mg/kg bolus followed by 0.125 mcg/kg [maximum 10 mcg/min] for 12 hours) or <a class="drug drug_general" data-topicid="10288" href="/d/drug information/10288.html" rel="external">tirofiban</a> (10 mcg/kg bolus followed by 0.15 mcg/kg for 18 to 24 hours) [<a href="#rid58">58</a>]. Abciximab was significantly superior to tirofiban in the composite end point of death, infarction, or the need for urgent revascularization at 30 days (6 versus 7.6 percent, hazard ratio 0.79)  (<a class="graphic graphic_figure graphicRef70472" href="/d/graphic/70472.html" rel="external">figure 1</a>). The magnitude and direction of the effect were similar for each component of the composite end point, but the benefit was due primarily to fewer MIs (5.4 versus 6.9 percent). The superiority of abciximab was independent of age, sex, or the use of <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> pretreatment.</p><p>Subgroup analysis revealed the benefit of abciximab was limited to patients undergoing stenting for an ACS, in whom platelet activation is more marked, and to nondiabetics, since the outcomes at 30 days were similar with the two drugs in diabetics [<a href="#rid59">59</a>]. However, these subgroup results should be interpreted with caution, given the increased probability of a chance occurrence with multiple looks at the data.</p><p>By six months of follow-up, there was no significant difference in the combined end point or the individual end points between the two drugs  (<a class="graphic graphic_figure graphicRef75026" href="/d/graphic/75026.html" rel="external">figure 2</a>) [<a href="#rid60">60</a>]. The 1.6 percent absolute benefit and 21 percent relative reduction in the combined end point at 30 days with abciximab had fallen to nonsignificant levels (0.5 percent and 4 percent, respectively). Although there remained a significant benefit with abciximab in the subgroup of patients with an ACS at six months, this effect was no longer present at one year [<a href="#rid61">61</a>].</p><p>In summary, the only benefit from abciximab in TARGET appeared to be a reduction in procedure-related MI, primarily in patients with an ACS [<a href="#rid60">60</a>]. This difference was evident in the early periprocedural period and may have been due to less effective platelet inhibition with <a class="drug drug_general" data-topicid="10288" href="/d/drug information/10288.html" rel="external">tirofiban</a> with the dosage regimen used (10 mcg/kg bolus followed by 0.15 mcg/kg per min for 18 to 24 hours) [<a href="#rid60">60</a>].</p><p>Two other studies also demonstrated reduced response to <a class="drug drug_general" data-topicid="10288" href="/d/drug information/10288.html" rel="external">tirofiban</a> using the 10 mcg/kg bolus. In one, the proportion of patients in whom there was ≥80 percent inhibition of platelet activation at 15 minutes was significantly higher with abciximab than tirofiban (93 versus 60 percent); <a class="drug drug_general" data-topicid="8918" href="/d/drug information/8918.html" rel="external">eptifibatide</a> was as effective as abciximab [<a href="#rid55">55</a>]. In the second, abciximab achieved &gt;90 percent inhibition of maximal platelet aggregation during the first 15 to 60 minutes, a critical interval after intervention-induced vascular injury, compared to only 61 to 66 percent inhibition with tirofiban [<a href="#rid57">57</a>].</p><p>A high-dose bolus regimen of <a class="drug drug_general" data-topicid="10288" href="/d/drug information/10288.html" rel="external">tirofiban</a> before high-risk PCI (25 mcg/kg bolus over three minutes, followed by 0.15 mcg/kg per min for 18 hours) was evaluated in the ADVANCE trial, in which 202 patients were randomly assigned to tirofiban or placebo in addition to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, and heparin [<a href="#rid62">62</a>]. The primary end point of death, MI, urgent target vessel revascularization, or bailout GP IIb/IIIa inhibitor therapy was significantly lower with tirofiban (20 versus 35 percent). This high-dose bolus with a 12-hour infusion was also used in the EVEREST trial cited above [<a href="#rid63">63</a>], and is being compared with abciximab in the TENACITY trial</p><p>The United States Food and Drug administration’s approved dosing for <a class="drug drug_general" data-topicid="10288" href="/d/drug information/10288.html" rel="external">tirofiban</a>, for its approved use in unstable angina/non-ST elevation myocardial infarction, is a 25 mcg/kg bolus within five minutes and then 0.15 mcg/kg/min for up to 18 hrs. The infusion rate is reduced 50 percent in patients with creatinine clearance of less than or equal to 60 mL/min. </p><p class="headingAnchor" id="H18"><span class="h1">ANTICOAGULANT THERAPY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">Unfractionated heparin</a> (UFH; with or without glycoprotein [GP] IIb/IIIa inhibitors), low molecular weight heparin, direct thrombin inhibitors, and oral anticoagulants have been studied in patients undergoing percutaneous coronary intervention (PCI). All patients undergoing PCI receive one of these. </p><p class="headingAnchor" id="H19"><span class="h2">Heparin</span><span class="headingEndMark"> — </span>Intravenous UFH is given during the procedure to prevent acute vessel closure due to thrombosis [<a href="#rid64">64</a>]. This practice was initiated when percutaneous transluminal coronary angioplasty was the procedure of choice and has been continued with the routine use of intracoronary stents. The dosing of heparin and the role of activated clotting time (ACT) monitoring during heparin therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Heparin'</a>.)</p><p>Bleeding complications resulting from the combined use of potent antiplatelet and anticoagulant agents are a major risk of PCI. The issue of whether heparin is necessary in patients at very low risk of ischemic complications after PCI was addressed in the CIAO trial of 700 patients already taking <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> and undergoing elective PCI for an uncomplicated lesion; the patients were randomly assigned to either UFH (70 to 100 international units/kg) or no heparin [<a href="#rid65">65,66</a>]. Patients with calcified, bifurcation, or long lesions, as well as those with thrombus, small vessels, and bypass graft lesions, were excluded. No patients in either group received GP IIb/IIIa inhibitor therapy. The primary end point of death, MI, or urgent target vessel revascularization at 30 days occurred more frequently in the heparin group (3.7 versus 2.0 percent), but this difference was not statistically significant. Although there were fewer bleeding events in the no-heparin group, too few events occurred to permit important conclusions.</p><p>Despite the results of this small study, we believe that anticoagulant therapy should be used in all low-risk patients. While bleeding risk is recognized as a major safety issue and safer strategies require investigation, the omission of any anticoagulant is not prudent with the current level of evidence. </p><p class="headingAnchor" id="H22"><span class="h2">Low molecular weight heparin</span><span class="headingEndMark"> — </span>Two studies have directly compared low molecular weight heparin to UFH in patients with stable coronary artery disease undergoing stenting and found no significant difference between the two:</p><p class="bulletIndent1"><span class="glyph">●</span>The STEEPLE safety trial randomly assigned 2528 patients presenting for elective PCI to <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> (a single intravenous bolus of either 0.50 or 0.75 mg/kg before PCI) or UFH [<a href="#rid67">67</a>]. There was a higher mortality rate among patients receiving the 0.50 mg/kg dose of enoxaparin than in either of the other two groups, causing the data monitoring committee to recommend termination of this dose late in the trial. There was an observed reduction in the primary end point of major and minor bleeding in the 0.75 mg/kg group compared with UFH (6.5 versus 8.5 percent), but the difference was not statistically significant. The incidence of major bleeding, which was a secondary end point, was significantly reduced with enoxaparin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 291 patients undergoing elective or urgent PCI who were randomly assigned to <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> or UFH (both groups received a glycoprotein IIb/IIIa inhibitor), there was no difference in the primary end point of bleeding, nor was there a difference in a composite of death, MI, or urgent target vessel revascularization at 48 hours or 30 days [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Bivalirudin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a>, with or without a GP IIb/IIIa inhibitor, was an acceptable alternative to heparin therapy in two randomized trials of predominantly stable or low-risk ACS patients (REPLACE-2 and ISAR-REACT 3). </p><p>In the REPLACE-2 trial, 6010 patients (85 percent of whom received a stent) were randomly assigned to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> with provisional GP IIb/IIIa inhibitor therapy or to heparin with planned GP IIb/IIIa inhibitor therapy; almost all patients received <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> pretreatment [<a href="#rid69">69</a>]. In the heparin arm, 97 percent received the "planned" GP IIb/IIIa inhibitor, while in the bivalirudin arm, only 7 percent received a "provisional" GP IIb/IIIa inhibitor, primarily for procedural or angiographic complications (eg, side branch closure, obstructive dissection, thrombus).</p><p>REPLACE-2 satisfied prespecified criteria for noninferiority (of <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a>) for the primary end point of death, MI, urgent revascularization, or in-hospital major bleeding and for the secondary end point of death, MI, or urgent revascularization. Interpretation and clinical application of the results of REPLACE-2 has centered on the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">Bivalirudin</a> was associated with a significant reduction in protocol-defined major bleeding (2.4 versus 4.1 percent) compared to heparin plus a GP IIb/IIIa inhibitor. However, major bleeding by TIMI criteria was similar for the two groups (0.6 versus 0.9 percent), and it has been argued that heparin dosing and higher-than-usual procedural ACT values may have accounted in part for the increase in TIMI minor bleeding seen with heparin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The heparin plus GP IIb/IIIa inhibitor group had a nonsignificant reduction in post-procedure non-ST elevation myocardial infarction (MI; 5.8 versus 6.6 percent), driven mostly by a reduction in intermediate (creatine kinase MB fraction [CK-MB] greater than five times normal) and large (CK-MB greater than 10 times normal) MIs. The clinical significance of this trend is uncertain.</p><p></p><p>In a subsequent analysis of longer-term outcomes, the incidence of death, MI, or any revascularization at six months was comparable for patients treated with <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> versus heparin plus GP IIb/IIIa inhibitor (18.8 versus 17.5 percent) [<a href="#rid70">70</a>]. Mortality at one year was also not significantly different (1.9 versus 2.5 percent).</p><p>This issue of how <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> compares to heparin without GP IIb/IIIa inhibitor therapy in stable or low-risk ACS patients (biomarker negative) was addressed in the ISAR-REACT 3 trial [<a href="#rid71">71</a>]. In this study, 4570 patients pretreated with <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 600 mg at least two hours before the procedure were randomly assigned to anticoagulation with either bivalirudin (0.75 mg per kilogram bolus, followed by 1.75 mg/kg/hour infusion for the duration of the procedure) or a high dose of UFH (140 units/kg). After 30 days, the following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>There was no significant difference in the incidence of the composite primary end point of death, MI, urgent target-vessel revascularization due to myocardial ischemia, or major bleeding during the index hospitalization between the <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> and heparin groups (8.3 versus 8.7 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The composite secondary end point of death, MI, or urgent target vessel revascularization due to myocardial ischemia was similar in the two groups (5.9 versus 5.0 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of protocol-defined major bleeding (using the same definition as in REPLACE-2) was significantly lower in the <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> group (3.1 versus 4.6 percent). Most of this difference was attributable to a decrease in hemoglobin ≥3g/dL with an overt source. There was no significant difference in the rate of transfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At one year, there was no significant difference in the incidence of the primary composite end point (17.1 versus 17.5 percent, respectively) [<a href="#rid72">72</a>].</p><p></p><p>However, the applicability of ISAR-REACT 3 to current practice is somewhat uncertain, as the dose of heparin was higher than that recommended in United States and European guidelines [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Heparin'</a>.)</p><p>The ISAR-REACT 3A study addressed this issue by treating 2505 similar patients with a lower-dose heparin bolus (100 international units/kg) and comparing their outcomes to the historical groups in ISAR-REACT 3 [<a href="#rid75">75</a>]. At 30 days, the rate of the primary composite end point was not statistically different between the two heparin doses. The rate of major bleeding was lower (3.6 versus 4.6 percent) with the 100 international units/kg dose, but did not achieve statistical significance. In addition, the lower dose was noninferior to <a class="drug drug_general" data-topicid="8792" href="/d/drug information/8792.html" rel="external">bivalirudin</a> with regard to the primary composite outcome. </p><p class="headingAnchor" id="H26"><span class="h2">Fondaparinux</span><span class="headingEndMark"> — </span>The heparin pentasaccharide analog <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> is a selective inhibitor of factor Xa. It is rarely used at the time of PCI in stable patients [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H99962965"><span class="h2">Warfarin</span><span class="headingEndMark"> — </span>Combined antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and thienopyridine produces significantly better outcomes than aspirin plus <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. In the STARS trial, for example, 1653 patients who received a<strong> stent </strong>were randomly assigned to aspirin, aspirin plus warfarin, or aspirin plus <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a> [<a href="#rid5">5</a>]. At 30 days, the incidence of the primary end point of events reflecting stent thrombosis (death, emergency coronary artery bypass graft surgery, Q wave myocardial infarction, or angiographically evident thrombosis) was significantly lower with aspirin plus ticlopidine (0.5 versus 2.7 with aspirin plus warfarin). (See <a class="local">'Efficacy and safety'</a> above and <a class="local">'Timing and dose'</a> above.)</p><p>The use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in patients who require both long-term anticoagulant and antiplatelet therapies is discussed below. (See  <a class="medical medical_review" href="/d/html/101552.html" rel="external">"Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention", section on 'Elective patients'</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>This topic reviews the studies that support the use of antithrombotic therapy, using both antiplatelet and anticoagulant drugs, during percutaneous coronary intervention with stenting. However, even with proper administration, thrombotic events can occur. In addition, clinically important bleeding is not uncommon. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Bleeding'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recommendations for the periprocedural use of antithrombotic therapy in patients with stable coronary disease are found elsewhere. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Summary and recommendations'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schwartz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318:1714.</a></li><li><a class="nounderline abstract_t">Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65:422.</a></li><li><a class="nounderline abstract_t">Kenaan M, Seth M, Aronow HD, et al. The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. J Am Coll Cardiol 2013; 62:2083.</a></li><li><a class="nounderline abstract_t">Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.</a></li><li><a class="nounderline abstract_t">Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.</a></li><li><a class="nounderline abstract_t">Schömig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997; 29:28.</a></li><li><a class="nounderline abstract_t">Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084.</a></li><li><a class="nounderline abstract_t">Schühlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997; 95:2015.</a></li><li><a class="nounderline abstract_t">Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597.</a></li><li><a class="nounderline abstract_t">Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126.</a></li><li><a class="nounderline abstract_t">Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001; 103:1403.</a></li><li><a class="nounderline abstract_t">Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624.</a></li><li><a class="nounderline abstract_t">Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99:2364.</a></li><li><a class="nounderline abstract_t">Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999; 34:1884.</a></li><li><a class="nounderline abstract_t">Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999; 34:1891.</a></li><li><a class="nounderline abstract_t">Dangas G, Mehran R, Abizaid AS, et al. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol 2001; 87:470.</a></li><li><a class="nounderline abstract_t">Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9.</a></li><li><a class="nounderline abstract_t">Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.</a></li><li><a class="nounderline abstract_t">Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.</a></li><li><a class="nounderline abstract_t">Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111:2560.</a></li><li><a class="nounderline abstract_t">Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44:2133.</a></li><li><a class="nounderline abstract_t">Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099.</a></li><li><a class="nounderline abstract_t">Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48:1339.</a></li><li><a class="nounderline abstract_t">von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112:2946.</a></li><li><a class="nounderline abstract_t">Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25:1903.</a></li><li><a class="nounderline abstract_t">Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48:931.</a></li><li><a class="nounderline abstract_t">Bates ER, Lau WC, Bleske BE. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation 2005; 111:2557.</a></li><li><a class="nounderline abstract_t">Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45:1392.</a></li><li><a class="nounderline abstract_t">Müller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108:2195.</a></li><li><a class="nounderline abstract_t">Widimsky P, Motovská Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients &gt; 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008; 29:1495.</a></li><li><a class="nounderline abstract_t">Schiele F, Meneveau N, Bassand JP. Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer? Eur Heart J 2008; 29:1475.</a></li><li><a class="nounderline abstract_t">Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010; 56:550.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361:2330.</a></li><li><a class="nounderline abstract_t">Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368:1303.</a></li><li><a class="nounderline abstract_t">Cavender MA, Bhatt DL, Stone GW, et al. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation 2016; 134:723.</a></li><li><a class="nounderline abstract_t">Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382:1981.</a></li><li class="breakAll">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm452172.htm (Accessed on June 23, 2015).</li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/204958Orig1s000ltr.pdf (Accessed on June 23, 2015).</li><li><a class="nounderline abstract_t">Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46:1833.</a></li><li><a class="nounderline abstract_t">Park KW, Kang SH, Park JJ, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety &amp; Effectiveness of Drug-Eluting Stents &amp; Anti-platelet Regimen). JACC Cardiovasc Interv 2013; 6:932.</a></li><li><a class="nounderline abstract_t">Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157:733.</a></li><li><a class="nounderline abstract_t">Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119:3207.</a></li><li><a class="nounderline abstract_t">Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159:284.</a></li><li><a class="nounderline abstract_t">EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352:87.</a></li><li><a class="nounderline abstract_t">Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341:319.</a></li><li><a class="nounderline abstract_t">Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354:2019.</a></li><li><a class="nounderline abstract_t">Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113:1.</a></li><li><a class="nounderline abstract_t">ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356:2037.</a></li><li><a class="nounderline abstract_t">O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618.</a></li><li><a class="nounderline abstract_t">Kastrati A, Mehilli J, Schühlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.</a></li><li><a class="nounderline abstract_t">Schömig A, Schmitt C, Dibra A, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005; 26:1379.</a></li><li><a class="nounderline abstract_t">Neumann FJ, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37:1323.</a></li><li><a class="nounderline abstract_t">Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106:1470.</a></li><li><a class="nounderline abstract_t">Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103:2572.</a></li><li><a class="nounderline abstract_t">Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89:647.</a></li><li><a class="nounderline abstract_t">Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888.</a></li><li><a class="nounderline abstract_t">Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105:2730.</a></li><li><a class="nounderline abstract_t">Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360:355.</a></li><li><a class="nounderline abstract_t">Mukherjee D, Topol EJ, Bertrand ME, et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 2005; 26:2524.</a></li><li><a class="nounderline abstract_t">Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44:14.</a></li><li><a class="nounderline abstract_t">Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006; 47:522.</a></li><li><a class="nounderline abstract_t">Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114:728S.</a></li><li><a class="nounderline abstract_t">Stabile E, Nammas W, Salemme L, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 2008; 52:1293.</a></li><li><a class="nounderline abstract_t">Dauerman HL. Coronary intervention without a safety net. J Am Coll Cardiol 2008; 52:1299.</a></li><li><a class="nounderline abstract_t">Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20.</a></li><li><a class="nounderline abstract_t">Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.</a></li><li><a class="nounderline abstract_t">Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292:696.</a></li><li><a class="nounderline abstract_t">Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688.</a></li><li><a class="nounderline abstract_t">Schulz S, Mehilli J, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010; 31:582.</a></li><li><a class="nounderline abstract_t">Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:216.</a></li><li><a class="nounderline abstract_t">Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.</a></li><li><a class="nounderline abstract_t">Schulz S, Mehilli J, Neumann FJ, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31:2482.</a></li><li><a class="nounderline abstract_t">Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111:1390.</a></li></ol></div><div id="topicVersionRevision">Topic 1577 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2967433" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407084" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055844" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11413167" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834303" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996291" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598866" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133509" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778323" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815866" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11245644" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931801" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10318654" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588198" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588199" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clopidogrel versus ticlopidine after intracoronary stent placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179539" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852999" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thrombotic thrombocytopenic purpura associated with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435254" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16516075" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809367" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582309" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750189" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010792" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260639" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15522469" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949482" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911717" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Loading, pretreatment, and interindividual variability issues with clopidogrel dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862408" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568892" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of statins on platelet inhibition by a high loading dose of clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441320" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clopidogrel pre-treatment in stable angina: for all patients&gt;6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503056" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688209" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915222" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intravenous platelet blockade with cangrelor during PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915221" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Platelet inhibition with cangrelor in patients undergoing PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23473369" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of platelet inhibition with cangrelor during PCI on ischemic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27482008" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011551" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011551" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011551" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286167" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24050860" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety&amp;Effectiveness of Drug-Eluting Stents&amp;Anti-platelet Regimen).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332203" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528339" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152228" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9672272" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10423466" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636365" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12106616" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145489" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11829701" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724302" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734767" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300442" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12234950" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11382726" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867064" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419425" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12057986" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241774" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16107485" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15234398" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458130" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822074" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antithrombotic therapy in patients undergoing coronary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929239" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929240" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Coronary intervention without a safety net.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957147" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570939" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588269" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304466" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703471" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150324" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386696" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769784" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20805113" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781750" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
